ArticleJournal of cachexia, sarcopenia and muscle2020
Handgrip weakness, low fat-free mass, and overall survival in non-small cell lung cancer treated with curative-intent radiotherapy.
Article in Journal of cachexia, sarcopenia and muscle, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pretreatment quality of life and survival in patients with lung cancer: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Physical function predicts mortality in patients with cancer: a systematic review and meta-analysis of observational studies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Pooled it
- Muscle Health and Prognosis in Patients With Cancer: New Insights.Journal of cachexia, sarcopenia and muscle · 2026Article
- Association of fat-free mass index and survival in patients with lung cancer: a multicenter cohort study.International journal of clinical oncology · 2026Article
- Prevalence and Development of Cachexia Before and After Diagnosis of Non-small Cell Lung Cancer.American journal of clinical oncology · 2025Article
- Nutritional assessments and interventions in head and neck, esophageal, rectal and lung cancers undergoing anticancer treatments: a literature review.Frontiers in oncology · 2025Review
- Complex situations in lung cancer: multifocal disease, oligoprogression and oligorecurrence.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Cachexia and Sarcopenia in Oligometastatic Non-Small Cell Lung Cancer: Making a Potential Curable Disease Incurable?Cancers · 2024Article
- Dietary vitamin K intake in relation to skeletal muscle mass and strength among adults: a cross-sectional study based on NHANES.Frontiers in nutrition · 2024Article
- Association of possible sarcopenia with all-cause mortality in patients with solid cancer: A nationwide multicenter cohort study.The journal of nutrition, health & aging · 2024Observational
- Incorporating Exercise Training into Cardio-Oncology Care: Current Evidence and Opportunities:JACC. CardioOncology · 2023Review
- A novel orthotopic mouse model replicates human lung cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2023Article
- Obesity and lung cancer-a narrative review.Journal of thoracic disease · 2023Review
- The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer.Journal of cachexia, sarcopenia and muscle · 2022Article
- Extracellular water to total body water ratio predicts survival in cancer patients with sarcopenia: a multi-center cohort study.Nutrition & metabolism · 2022Article
- Physical exercise at the crossroad between muscle wasting and the immune system: implications for lung cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2022Review
- Combination of Nutritional Risk Index and Handgrip Strength on the Survival of Patients with Cancer Cachexia: A Multi- Center Cohort Study.Journal of inflammation research · 2022Article
- Muscle weakness as an additional criterion for grading sarcopenia-related prognosis in patients with cancer.Cancer medicine · 2022Article
- Muscle strength and muscle mass as predictors of hospital length of stay in patients with moderate to severe COVID-19: a prospective observational study.Journal of cachexia, sarcopenia and muscle · 2021Observational
- Preoperative paraspinous muscle sarcopenia and physical performance as prognostic indicators in non-small-cell lung cancer.Journal of cachexia, sarcopenia and muscle · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAssessment of handgrip strength and fat-free mass provides quick and objective information on muscle performance and mass that might complement subjective World Health Organization Performance Status (WHO PS). We investigated to what extent the presence of pre-treatment handgrip weakness and low fat-free mass index (FFMI) provides additional prognostic information on top of well-established prognostic factors (including WHO PS) in non-small cell lung cancer (NSCLC) patients selected for curative-intent (chemo)radiation.
methodsProspectively, patients with early and locally advanced NSCLC (stages I-III) treated with (chemo)radiation were enrolled. Handgrip weakness and low FFMI, derived from bioelectrical impedance analysis, were defined using normative values and were correlated with overall survival (OS).
resultsWe included 936 patients (age 68 ± 10 years; 64% male; 19% stage I, 9% stage II, and 72% stage III disease; 26% handgrip weakness; 27% low FFMI). In patients with good performance status (WHO PS 0 or 1), handgrip weakness and low FFMI were significant prognostic factors for OS, after adjustment for age, gender, disease stage, and co-morbidities. The combined presence of handgrip weakness and low FFMI was a strong prognostic factor for OS when compared with patients with normal handgrip strength and FFMI (hazard ratio: 1.79, 95% confidence interval: 1.34-2.40, P < 0.0001). In patients with impaired performance status (WHO PS ≥ 2, 19% of sample), handgrip weakness and low FFMI were not related to OS.
conclusionsIn early and locally advanced NSCLC patients treated with curative-intent (chemo)radiation who have good WHO PS, patients with combined handgrip weakness and low FFMI have the worst prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.